A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims To conduct a medication screening trial on the efficacy of olanzapine, valproate or coenzyme Q10/L‐carnitine combination versus placebo for the treatment of cocaine dependence. Design A four‐arm, modified blinded, parallel group study in an out‐patient setting using the Cocaine Rapid Efficacy and Safety Trials (CREST) study design. Setting The study was performed at the New York Medications Development Research Unit (MDRU). Participants All participants met Diagnostic and Statistical Manual version IV (DSM‐IV) criteria for cocaine dependence and provided at least two urine samples positive for benzoylecgonine (BE) during the 2‐week screening period. Sixty‐eight participants were enrolled with 39 completing the study. Intervention After a 2‐week screening period, 68 subjects were assigned randomly to receive either olanzapine (10 mg/day), valproate (1500 mg/day), coenzyme Q10 (200 mg/day) and L‐carnitine (500 mg/day) combination or placebo for an 8‐week treatment period. All subjects also received individual cognitive behavioral counseling during treatment. Measurements Primary outcome measures included quantitative urine benzoylecgonine (BE) levels, self‐report of drug use, and global impression scores. Secondary outcomes included cocaine craving, study retention and related psychosocial measures. Safety measures included adverse event monitoring, vital signs, and extrapyramidal side‐effects tests. Results Study retention was similar across all treatment groups, and all groups showed improvement across most measures of treatment efficacy over the duration of the study. None of the study medications, however, were superior to placebo on any of the primary or secondary outcome measures. Cocaine use, as measured by urine BE levels and self‐report, was not significantly lower than placebo in any of the drug treatment groups. All study medications were equally well tolerated, and few medication side effects were observed. Conclusion This pilot study does not support the effectiveness of olanzapine, valproate or coenzyme Q10/ L‐carnitine combination for the treatment of cocaine dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503
Volkow, N. D., Fowler, J. S., Wang, G., Hitzemann, R., Logan, J., Schlyer, D. J., Dewey, S. L., & Wolf, A. P. (1993) · Synapse · doi:10.1002/syn.890140210 · Cited by 924
Self-citationEnergy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Anticonvulsant modification of cocaine-induced toxicity in the rat
Derlet, R. W., & Albertson, T. E. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90010-o · Cited by 59
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates
Bodis-Wollner, I., Chung, E., Ghilardi, M. F., Glover, A., Onofrj, M., Pasik, P., & Samson, Y. (1991) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02251137 · Cited by 51
Divalproex Sodium in Substance Abusers With Mood Disorder
Albanese, M. J., Clodfelter, R. C., & Khantzian, E. J. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1205 · Cited by 40
Cited by
Hjorthøj, C. R., Hjorthøj, A. R., & Nordentoft, M. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.11.025 · Cited by 364
Striatal ups and downs: Their roles in vulnerability to addictions in humans
Leyton, M., & Vezina, P. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.01.018 · Cited by 165
Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., & Halpern, C. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8049 · Cited by 161
Antipsychotic medications for cocaine dependence
Indave, B. I., Minozzi, S., Pani, P. P., & Amato, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006306.pub3 · Cited by 122
Swann, A. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05146.x · Cited by 109
Metadata
- Authors
- Reid, M. S., Casadonte, P., Baker, S., Sanfilipo, M., Braunstein, D., Hitzemann, R., Montgomery, A., Majewska, D., Robinson, J., & Rotrosen, J.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2005-02-24
- Volume
- 100
- Issue
- s1
- Pages
- 43-57
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2047453140
- Cited by
- 54
- References
- 6
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence. https://app.cochat.ai/papers/10.1111/j.1360-0443.2005.00990.x
- The paper
- Reid, M. S., Casadonte, P., Baker, S., Sanfilipo, M., Braunstein, D., Hitzemann, R., Montgomery, A., Majewska, D., Robinson, J., & Rotrosen, J. (2005). A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence. Addiction. https://doi.org/10.1111/j.1360-0443.2005.00990.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.